Media should be required to reveal any conflicts of interest and paid interest when questioning guests. For example, questions regarding the risk of any Pharm product can come with the commentator/interviewer working indirectly for Pharm since their paycheck relies on the advertisements for their station. Therefore, just like research studies list their conflicts of interests or potential bias from paid interests so should media that citizens use to get information about important topics that impact health and voting.
Below is information on Pharm spending in media:
Pharma TV Ad Spending
Based on the provided search results, here’s a breakdown of the estimated TV ad spend for pharmaceutical companies in the United States:
- Total pharma TV ad spend in 2020: $4.58 billion (according to the first search result)
- Top pharma companies’ TV ad spend in 2023:
- AbbVie: $861.4 million (across Skyrizi, Rinvoq, and Vraylar)
- Sanofi and Regeneron’s Dupixent: $307.2 million
- Other top-spending drugs (not specified): unknown
- Quarterly TV ad spend in Q1 2023: $588 million (from medical and pharmaceutical advertisers, with AbbVie, GSK, and Pfizer being the top three spenders)
- Year-over-year increase in Q1 2023 TV ad spend: 13% (from medical and pharmaceutical advertisers)